Risdiplam
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Risdiplam |
| DrugBank ID | DB15305 |
| Brand Names (EU) | Evrysdi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.45% |
Approved Indication (EMA)
Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acne (disease) | 99.45% | DL |
| 2 | drug-induced osteoporosis | 97.72% | DL |
| 3 | zinc, elevated plasma | 97.32% | DL |
| 4 | common wart | 97.21% | DL |
| 5 | metastatic melanoma | 96.84% | DL |
| 6 | dermatitis | 96.62% | DL |
| 7 | non-cutaneous melanoma | 96.18% | DL |
| 8 | acrodermatitis chronica atrophicans | 96.11% | DL |
| 9 | epithelioid cell melanoma | 95.93% | DL |
| 10 | eyelid melanoma | 95.88% | DL |
| 11 | scrotum melanoma | 95.75% | DL |
| 12 | neonatal dermatomyositis | 95.74% | DL |
| 13 | multiple endocrine neoplasia | 95.58% | DL |
| 14 | choroideremia | 95.51% | DL |
| 15 | acne keloid | 95.40% | DL |
| 16 | CDK4 linked melanoma | 95.39% | DL |
| 17 | superficial spreading melanoma | 95.39% | DL |
| 18 | malignant melanoma of the mucosa | 95.39% | DL |
| 19 | nodular malignant melanoma | 95.39% | DL |
| 20 | amelanotic skin melanoma | 95.39% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.